
Based on recent data on omicron variant susceptibility to monoclonal antibodies, the Food and Drug Administration revised its emergency use authorizations for the combination therapies bamlanivimab and etesevimab and REGEN-COV (casirivimab and imdevimab) to exclude geographic regions where the omicron COVID-19 variant predominates.